Skip to content
MARKETS / NYSE / DVA
NYSE · SERVICES-MISC HEALTH & ALLIED SERVICES, NEC · LARGE CAP

Davita Inc. DVA

19 fiscal years on record · USD · FY2025 reported · SEC filings only
$13.6B
▲ 6.5% YoY
$746.8M
▼ 20.2% YoY
$1.3B
▼ 10.6% YoY
In brief

What this company does

DaVita provides dialysis, administrative, and related laboratory services to patients with chronic kidney failure in the United States. As of December 31, 2025, the company provided dialysis, administrative and related laboratory services to approximately 200,500 patients. As of December 31, 2025, the company employed approximately 78,000 teammates, with approximately 72% of them located within the United States. The company also maintains other ancillary services and investments outside of its U.S. dialysis, U.S. integrated kidney care, and international operations. As of December 31, 2025, the company's international operations provided dialysis and administrative services to 585 outpatient dialysis centers located in 14 countries outside the United States, serving approximately 94,500 patients. The company's U.S. integrated kidney care business provided integrated care and disease management services to 66,000 patients in risk-based integrated care arrangements and to an additional 9,400 patients in other integrated care arrangements across the United States as of December 31, 2025.

Written from the business description in DAVITA INC.'s annual report to the U.S. Securities and Exchange Commission, filed 11 February 2026. Every sentence was checked against that document before publication.

Growth
USD 13.6B
Revenue, FY2025 · full 19-year series below
Revenue $B Net income $B
FY2025 · Revenue 13.6 · Net income 0.7
5B10B2007201020132016201920222025
Compound annual growth
+5.5%
+3.4%
+3.2%
+5.4%
+10.0%
−0.7%
+10.7%
+4.2%
+18.9%
+9.3%
+22.9%
+17.7%
−2.1%
+9.6%
+5.8%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +3.4% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
8 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 15.0% · Net 7.9%
10%20%2007201020132016201920222025
ROE
FY2024 · ROE 159.1%
50%100%150%2007201020132016201920222025

Cash & shareholders
USD 1.3B
returned in FY2025 · dividends + net buybacks
Free cash flow $B
FY2025 · FCF 1.3
0.5B1.0B2007201020132016201920222025
Net buybacks $B Dividends $B
FY2025 · Dividends 0.0 · Net buybacks 1.3
0.8B1.6B200720092011201620182020202220242025

USD 1.3B in buybacks — 175% of the year's profit, so the payout drew on cash built up earlier.

Total assetsUSD 17.5B
EquityUSD -651.1M
CashUSD 676.4M
Gross debtUSD 10.2B
Net debtUSD 9.5B
Current ratio1.29×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 19-year record
19 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B13.612.812.111.611.611.611.410.710.19.710.012.811.88.26.76.2···
Operating income $B2.02.11.61.31.81.71.61.51.82.01.11.81.61.31.21.00.90.90.9
EBITDA $B2.82.82.32.12.52.32.22.12.42.51.62.21.91.61.41.21.21.1·
Income tax $B0.30.30.20.20.30.30.30.30.30.40.20.40.40.40.30.30.30.20.2
Net income $B0.70.90.70.61.00.80.80.20.70.90.30.70.60.50.50.40.40.40.4
Free cash flow $B1.31.51.51.01.31.31.30.81.01.10.80.81.20.60.80.60.40.30.3
EPS, diluted $9.8410.737.425.858.906.315.270.923.474.291.253.332.952.742.483.944.063.533.55
Dividend / sh $···················
Payout %00000000···········
ROE %·159.178.276.491.544.027.83.814.218.55.415.115.518.223.219.721.721.2·
Shares out B0.070.080.090.090.100.110.130.170.180.190.210.220.210.210.090.100.100.10·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Compare

This company against its peers

Provenance
Company facts, as filed
How we verify · 0 failures in 74 reconciliationsAUDITED

Reconciled in 19 of 19 fiscal years. 2 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityServices-Misc Health & Allied Services, NEC
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2007

Share this section

Download image